24 April 2015
Advanced Medical Solutions Group plc
(“AMS” or the “Company”)
Correction to Exercise of share options and Directors’ dealings
In the Director Dealing announcement released earlier today under RNS No 3200L, the announcement omitted the date on which both the share incentive awards were exercised and the Company was informed of such exercise. This information has been included below. All other details remain unchanged.
Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), the global medical technology company, was informed on 23 April 2015 that Mary Tavener, Group Finance Director, on 23 April exercised certain share incentive awards as outlined below.
In order to cover the exercise cost and the tax payable on this exercise Mary Tavener has sold 55,000 Ordinary Shares of 5p each on 23 April 2015 at 139.25 pence per share as detailed below.
A summary of Ms Tavener’s beneficial interest in Ordinary Shares and Ordinary Shares under incentive schemes is summarised in the table below.
|
|
Number prior to transaction |
Number exercised |
Shares acquired |
Shares sold |
Resultant interest |
|
Ordinary Shares |
1,774,470 |
|
104,957 |
55,000 |
1,824,427 |
|
Long Term Incentive Plan |
624,611 |
97,829 |
– |
– |
526,782 |
|
Deferred Share Bonus Plan |
18,494 |
7,128 |
– |
– |
11,366 |
|
Deferred Annual Bonus Plan |
36,538 |
– |
– |
– |
36,538 |
– Ends –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
|
+44 (0) 1606 545508 |
|
Consilium Strategic Communications Mary-Jane Elliot / Jonathan Birt / Matthew Neal / Ivar Milligan
|
+44 (0) 20 3709 5700 AMS@consilium-comms.com |
|
Investec Bank plc (NOMAD & Broker) Gary Clarence / Daniel Adams / Patrick Robb |
+44 (0) 20 7597 5970 |
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 472 employees. For more information please see www.admedsol.com.
This information is provided by RNS
END
RDSEAKLLAFXSEFF